Cyclic nucleotide phosphodiesterases: Pharmacology, biochemistry and function

Pharmacology and Therapeutics

Volumn 51, Issue 1, 1991, Pages 13-33

  Thompson, W Joseph ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BIPYRIDINE; CYCLIC GMP; CYCLIC NUCLEOTIDE PHOSPHODIESTERASE; DIPYRIDAMOLE; ISOENZYME; ISOQUINOLINE DERIVATIVE; ROLIPRAM; SQ 65442; TREQUINSIN; VINPOCETINE; ZALDARIDE MALEATE; ZAPRINAST;

BIOCHEMISTRY; HUMAN; NONHUMAN; PHARMACOLOGY; PRIORITY JOURNAL; REVIEW;

2',3'-CYCLIC-NUCLEOTIDE PHOSPHODIESTERASES; AMINO ACID SEQUENCE; ANIMAL; BASE SEQUENCE; ISOENZYMES; MOLECULAR SEQUENCE DATA; PHOSPHODIESTERASE INHIBITORS; SEQUENCE HOMOLOGY, NUCLEIC ACID;

EID: 0025999955     PISSN: 01637258     EISSN: None     Source Type: Journal    
DOI: 10.1016/0163-7258(91)90039-O     Document Type: Article

References (201)

1. A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithromotic properties
2. Cyclic nucleotide phosphodiesterases properties activators inhibitors structure-activity relationships and possible role in drug development
3. Analysis of the binding sites for the cardiotonic phosphodiesterase inhibitor [3H]-LY186126 in ventricular myocardium
4. Cyclic AMP turnover in response to prostaglandins in intact platelets: evidence for separate stimulatory and inhibitory prostaglandin receptors
5. Role of high affinity cAMP phosphodiesterase activities in the response of S49 Cells to agonists
6. The role of cyclic nucleotides in atrial natriuretic peptide-mediated inhibition of aldosterone secretion
7. Multiple isozymes of cyclic nucleotide phosphodiesterase
8. Multiple phosphodiesterase isozymes: background, nomenclature and implications
9. Primary sequences suggest selective inhibition of individual cyclic nucleotide phosphodiesterase is possible
10. Discriminative insulin antagonism of stimulatory effects of various cAMP analogs on adipocyte lipolysis and hepatocyte glycogenolysis
11. Rat mast cell high affinity cyclic nucleotide phosphodiesterases: separation and inhibitory effects of two antiallergic agents
12. Mechanism of action and cardiotonic activity of a new phosphodiesterase inhibitor, the benzimidazole derivative adibendan (BM 14,478), in Guinea-Pig Hearts
13. Inhibition of gastric acid secretion in vivo and in vitro by new calmodulin antagonist, CGS 9343B
14. Resolution of soluble rat cardiac phosphodiesterase by high performance liquid chromatography
15. Dibenzoquinazoline diones as antihypertensive cyclic guanosine monophosphate phosphodiesterase inhibitors
16. Retinal degeneration in the RD mouse is caused by a defect in the beta subunit
17. Purification of an insulin-sensitive cyclic AMP phosphodiesterase from rat liver
18. Selective inhibition of cAMP phosphodiesterase III Activity by the cardiotonic agent saterinone in guinea pig myocardium
19. Phosphodiesterase after twenty years: an introduction
20. Adenosine 3′,5′-phosphate in biological materials
21. Action of the cardiac alpha-1-adrenergic receptor: activation of cyclic AMP degradation
22. Defect in Cyclic AMP phosphodiesterase due to the dunce mutation of learning in Drosophilia Melanogaster
23. Effects of selective phosphodiesterase inhibition on cyclic AMP hydrolysis in rat cerebral cortical slices
24. Structure-function relationships among cyclic nucleotide phosphodiesterases
25. Identification of a conserved domain among cyclic nucleotide phosphodiesterases from diverse species
26. Identification of a noncatalytic cGMP-binding domain conserved in both the cGMP stimulated and photoreceptor cyclic nucleotide phosphodiesterase
27. Inhibitors and activators of cyclic nucleotide phosphodiesterase
28. Molecular analysis of cDNA clones and the corresponding genomic coding sequences of the Drosophila dunce + gene the structural gene for cAMP phosphodiesterase
29. Isolation and characterization of a mammalian gene encoding a high affinity cAMP phosphodiesterase
30. New positive inotropic agents in the treatment of congestive heart failure
31. Structure and function of the rolipram-sensitive low Km cyclic AMP phosphodiesterases: A family of highly related enzymes
32. Selectivity of action can be achieved with compounds acting at second messenger targets
33. Regulation of intracellular calcium levels in cultured vascular smooth muscle cells: reduction of calcium by atriopeptin and 8-bromo-cyclic GMP-dependent protein kinase
34. Assessment of selective inhibition of rat cerebral cortical calcium-dependent and calcium-independent phosphodiesterases in crude extracts using deoxycyclic AMP and potassium ions
35. 1-(4-Aminophenyl) isoquinoline derivatives: potent inhibitors of calcium-independent and calcium-dependet phosphodiesterases from rat cerebral cortex
36. + gene
37. Regulation of cyclic GMP metabolism in toad photoreceptors
38. Purification of the putative hormone-sensitive cyclic AMP phosphodiesterase from rat adipose tissue using a derivative of cilostamide as a novel affinity ligand
39. Haemodynamic profile of an inhibitor of phosphodiesterase III abibendan (BM 14478) comparison with nitroprusside and dobutamine in conscious dogs
40. Effects of new inotropic agents on cyclic nucleotide metabolism and calcium transients in canine ventricular muscle
41. Catalytic and kinetic properties of purified high-affinity cyclic AMP phosphodiesterase from dog kidney
42. A Mechanism in the control of cellular cAMP level: the activation of a calmodulin-sensitive phosphodiesterase by a rise of intra-cellular free calcium
43. Modulation of cAMP: Mechanism for positive inotropic action
44. Muscarinic cholinergic receptors of two cell lines that regulate cyclic AMP metabolism by different molecular mechanisms
45. m cyclic AMP phosphodiesterase in cardiac cells
46. Cyclic AMP phosphodiesterases and calcium current regulation in cardiac cells
47. Relaxation of vascular and tracheal smooth muscle by cyclic nucleotide analogs that preferentially activate purified cGMP-dependent protein kinase
48. Cyclic GMP-binding cyclic GMP-specific phosphodiesterase from lung
49. 2+, calmodulin-dependent protein kinase
50. Characterization of a bovine cone photoreceptor phosphodiesterase purified by cyclic GMP-sepharose chromatography
51. Inhibition and stimulation of photoreceptor phosphoiesterases by dipyridamole and M&B 22,948
52. 4Cl) cells
53. Three new potential cAMP affinity labels. Inactivation of human platelet Low Km cAMP phosphodiesterase by 8-[(4-bromo-2,3-dioxobutyl)adenosine 3′,5′-cyclic monophosphate
54. Purificatiin of calmodulin-stimulated cyclic nucleotide phosphodiesterase by monoclonal antibody affinity chromotography
55. Differential inhibition of cardiac cyclic nucleotide phosphodiesterase isozymes by cardiotonic drugs
56. Isolation and characterization of bovine cardiac muscle cGMP-inhibited phosphodiesterase: a receptor for new cardiotonic drugs
57. Rat homologs of the Drosphila dunce gene code for cyclic AMP phosphodiesterase sensitive to rolipram and RO 20-1724
58. Selective inhibitors of three forms of cyclic nucleotide phosphodiesterases
59. The use of selective inhibitors and computer modelling to evaluate the role of specific high affinity cyclic AMP phosphodiesterases in the hormonal regulation of hepatocyte intracellular cyclic AMP concentrations
60. Cyclic nucleotide phosphodiesterases in liver
61. Molecular properties of the cGMP cascade of vertebrate photoreceptors
62. Hemodynamic effects of a new type III phosphodiesterase inhibitor (CI 914) for congestive heart failure
63. Acute neurohormonal and hemodynamic response to a new peak III phosphodiesterase inhibitor (ICI 153,110) in patients with chronic heart failure
64. Inhibitors of cyclic AMP phosphodiesterase. 1. Analogues of cilostimide and anagrelide
65. Effects of N-6(-aminohexyl)-5-chloro-1-naphthalenesulfonamine and other calmodulin antagonists (calmodulin interacting agents) on calcium-induced contraction of rabbit aortic strips
66. Tissue distribution and selective inhibition of subtypes of high affinity cAMP phosphodiesterase
67. LY-195115: A potent, selective inhibitor of cyclic nucleotide phosphodiesterase located in the sarcoplasmic reticulum
68. In vitro vascular relaxation by new inotropic agents: relationship to phosphodiesterase inhibition and cyclic nucleotides
69. A method to assess concomitant cardiac phosphodiesterase inhibition and positive inotropy
70. Assay of cyclic nucleotide phosphodiesterase using dadiolabeled and fluorescent substrates
71. Does the positive inotropic action of a novel cardiotonic agent, MCI-154, involve mechanisms other than cyclic AMP?
72. Subcellular distribution of high affinity type IV cyclic AMP phosphodiesterase in rabbit ventricular myocardium relationships to the effects of cardiotonic drugs
73. Cyclic nucleotide-dependent protein kinase. IV. Widespread occurrence of adenosine 3′,5′-monophosphate-dependent protein kinase in various tissues and phyla of the animal kingdom
74. Trequinsin, a potent new anti-hypertensive vasodilator in the series of 2-(arylimino)-3-alkyl-9,10-dimethoxy-3,4,6,7, -tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-ones
75. Calcium-induced exposure of a hydrophobic surface on calmodulin
76. Purification and characterization of cGMP-inhibited low Km cAMP phosphodiesterase (PDE) from human placental cytosolic fractions
77. Amino acid sequence of the cyclic GMP stimulated cyclic nucleotide phosphodiesterase from bovine heart
78. Atrial natriuretic factor reduces cyclic adenosine monophosphate content of human fibroblasts by enhancing phosphodiesterase activity
79. Bovine cone photoreceptor cGMP phosphodiesterase structure deduced from a CDNA clone
80. Cyclic GMP and mechanism of vasolidation
81. ++ by cAMP in vascular smooth muscle cells
82. Relaxant effects of the selective phosphodiesterase inhibitors milrinone and OPC 3911 on isolated human mesenteric vessels
83. Lack of beneficial effects of milrinone in severe septic shock
84. Effects of isozyme-selective phosphodiesterase inhibitors on rat aorta and human platelets: smooth muscle tone, platelet aggregation and cAMP levels
85. Beta subunit of bovine rod photoreceptor cGMP phosphodiesterase. comparisonwith the phosphodiesterase family
86. m rolipram-senstive cyclic AMP phosphodiesterase
87. Cyclic GMP and photoreceptor function
88. Characterization of cyclic nucleotide phosphodiesterase from cultured bovine aortic endothelial cells
89. Selective inhibition of cyclic nucleotide phosphodiesterases of human, bovine and rat aorta
90. High concentrations of a cGMP-stimulated phosphodiesterase mediate ANP-induced decreases in cAMP and steroidogenesis in adrenal glomerulosa cells
91. m cAMP phosphodiesterase: probable target for antithrombotic agents
92. Subcellular localization and biological function of specific cyclic nucleotide phosphodiesterases
93. Cyclic GMP-inhibited cyclic nucleotide phosphodiesterases
94. Cyclic GMP-stimulated cyclic nucleotide phosphodiesterases
95. Phosphodiesterase inhibitors induce endothelium-dependent relaxation of rat and rabbit aorta by potentiating the effects of spontaneously released endothelium-derived relaxing factor
96. m cAMP phosphodiesterase (CGI PDE)
97. Y-590 (a new pyridazinone derivative), a potent anti-thrombotic agent II. Inhibition of platelet phosphodiesterase
98. Bemoradan—a novel inhibitor of the rolipram-insensitive cyclic AMP phosphodiesterase from canine heart tissue
99. Cardiotonic Agents 8 Selective inhibitors of adenosine 3′5′-cyclic phosphate phosphodiesterase III Elaboration of a five-point model for positive inotropic activity
100. Involvement of rolipram-sensitive cyclic AMOP phosphodiesterase in the regulation of cardiac contraction
101. Acute hemodynamic and hormonal effect of CI-930, a new phosphodiesterase inhibitor, in severe congestive heart failure
102. Characterization of particulate cyclic nucleotide phosphodiesterases from bovine brain: purification of a distinct cGMP-stimulated isozyme
103. The effects of siguazodan, a selective phosphodiesterase inhibitor, on human platelet function
104. Selective inhibition of the of the cyclic AmP phosphodiesterase from rat brain by the neutropic compound rolipram
105. Isolation of similar rolipram inhibitable, cyclic AMO specific phosphodiesterases from rat brain and heart
106. The ability of denbufylline to inhibit cyclic nucleotide phosphodiesterase and its affinity for adenosine receptors and the adenosine re-uptake site
107. Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isozymes
108. Inhibitors of cyclic AMP phosphodiesterase in medicinal plants
109. Inhibition of adenosine 3′,5′-cyclic monophosphate phosphodiesterase by phenolic constituents of mulberry tree
110. CGS 9343B, a novel, potent, and selective inhibitor of calmodulin activity
111. ++ and cAMP phosphodiesterase activity by milrinone
112. Cyclic AMP and cyclic GMP phosphodiesterases: target for drug development
113. Tissue specificity of cAMP phosphodiesterase inhibitors: rolipram, amrinone, enoximone, piroximone, and imazodan
114. Stimulation of guanosine 3′,5−monophosphate phosphodiesterase activity by adrenocorticotropic hormone-activated increase of guanosine 3′,5′-monophosphate in isolated adrenocortical Carcinoma Cells
115. Molecular characterization of human and bovine rod photoreceptor cGMP phosphodiesterase alpha subunit and chromosomal location of the human gene
116. Proteolysis of cyclic AMP phosphodiesterase-II attenuates its ability to be inhibited by compounds which exert positive inotropic actions in cardiac tissue
117. Comparison of cyclic nucleotide phosphodiesterase isoforms from rat heart and bovine aorta
118. Specific antibodies and the selective inhibitor ICI 118233 demonstrate that the hormonally stimulated “dense-vesicle” and peripheral-plasma-membrane cyclic AMP phosphodiesterases display distinct tissue distributions in the rat
119. The identification of a new cyclic nucleotide phosphodiesterase activity in human and guinea-pig cardiac ventricle
120. Cloning a carboxy-terminal domain of the rat cGMP-stimulated phosphodiesterase by polymerase chain reaction
121. Bipyridine cardiotonics: the three-dinmensional structures of amrinone and milrinone
122. Dihydropyridazinone cardiotonics: the discovery and inotropic activity of 1,3-dihydro-3′,3′,dimethyl-5(1,4,5,6,-tetrahydro-6-oxo-3-pyridazinyl)-2H -indol-2-one
123. Molecular structure of the dihydropyridazinone cardiotonic 1,3-dihydro-3,3-dimethyl-5-(1,4,5,6-tetrahydro-6-oxo-3-pyridazinyl)-2H-indol-2-one, a potent inhibitor of cyclic AMP phosphodiesterase
124. Variation of the inhibition of calmodulin dependent cyclic AMP phosphodiesterase amongst analogues of tamoxifen: correlations with cytotoxicity
125. HL 725, an extremely potent inhibitor of platelet phosphodiesterase and induced platelet aggregation in vitro
126. Differences in the association of calmodulin with cyclic nucleotide phosphodiesterase in relaxed and contracted arterial strips
127. Cloning and characterization of the high-affinity cAMP phosphodiesterase of Saccharomyces cerevisiae
128. Phosphodiesterase-inhibiting properties of newer inotropic agents
129. Unusual stereospecificity of the potential antidepressant rolipram on the cyclic AMP generating system from rat brain cortex
130. Rolipram, a stereospecific inhibitor of calmodulin-independent phosphodiesterase, causes beta-adrenoceptor subsensitivity in rat cerebral cortex
131. 4-(3-Cyclopentyloxy-4-methoxyphenyl)-2-pyrrolidone (ZK 62711): a potent inhibitor of adenosine cyclic 3′,5′-monophosphate phosphodiesterases in homogenates and tissue slices from rat brain
132. Regulation of cAMP concentration by calmodulin-dependent cyclic nucleotide phosphodiesterase
133. Structure-activity relationships for inhibitors of phosphodiesterase from erythrocytes and other tissues
134. Stimulation of the insulin-sensitive cAMP phosphodiesterase by an ATP-dependent soluble factor from insulin-treated rat adipocytes
135. Pharmacological modulation of phosphorylation mechanisms in heart and vasculature
136. Differential pharmacological sensitivioty of cyclic phosphodiesterase isozynes from cardiac muscle, arterial and airway smooth muscles
137. m cyclic AMP phosphodiesterase and activation of the cyclic AMP system in vascular smooth muscle by milrinone
138. m cyclic nucleotide phosphodiesterase isozymes in human cardiac muscle from normal and cardiomyopathic subject
139. m cyclic GMP phosphodiesterases and potentiation of guanylate cyclase activators by cicletanine
140. Effects of SK&F 94120, an inhibitor of cyclic nucleotide phosphodiesterase type III, on human platelets
141. Cadiotonic agents. 7. Inhibition of separated forms of cyclic nucleotide phosphodiesterase from guinea pig cardiac muscle by 4,5-dihydro-6-[4-(1H-imidazol-l-yl)phenyl]-3(2H)-pyridazinones and related compounds. Structure-activity relationships and correlatioon with in vivo positive inotropic activity
142. m cAMP phosphodiesterase in regulation of cAMP-dependent protein kinase and lipolysis in rat adipocytes
143. Lack of inotropic selectivity of phosphodiesterase enzyme inhibitors in vitro
144. Angiotensin decreases cyclic GMP accumulation produced by atrial natriuretic factor
145. Bronchodilator activity of a nonxanthine phosphodiesterase inhibitor: 2,4-diamino-cyano-6-bromopyridine (compound 1)
146. Insulin control of cyclic AMP phosphodiesterase
147. Role of selective cyclic GMP phosphodiesterase inhibition in the myorelaxant actions of M&B 22948, MY-5445, vinpocetine and 1-methyl-3-isobutyl-8-(methylamino)xanthine
148. Pig aortic endothelial cell cyclic nucleotide phosphodiesterases
149. The Biology of Cyclic Nucleotide Phosphidiesterases and Phosphoprotein Research, Vol. 25, Advances in Second Messenger and Phosphoprotein Research
150. Nomenclature recommendation
151. Cyclic nucleotide phosphodiesterases
152. General properties of multiple molecular forms of cyclic nucleotide phosphodiesterase in the nervous system
153. Molecular properties of cyclic nucleotide phosphodiesterase isozymes
154. Direct photolabeling of the cGMP-stimulated cyclic nucleotide phosphodiesterase
155. The acute toxic effect of the phosphodiesterase inhibitor rilopram on plasma osmolality
156. m phosphodiesterase inhibitor denbufylline enhances neuronal excitability in guinea pig hippocampus in vitro
157. Molecular cloning of rat homologues of the Drosophilia melanogaster dunce cAMP phosphodiesterase: evidence for a family of genes
158. The mRNA encoding a high-affinity cAMP phosphodiesterase is regulated by hormones and cAMP
159. Effects of cilostazol, a selective cAMP phosphodiesterase inhibitor on the contraction of vascular smooth muscle
160. Comparison of putative cGMP-binding regions in bovine brain and cardiac cGMP-stimulated phosphodiesterases
161. Identification of the phosphodiesterase regulated by muscarinic cholinergic receptors of 1321N1 human astrocytoma cells
162. Determination of cyclic nucleotide phosphodiesterase activity in cellular systems by ion-pair reversed-phase
163. Characterization of a purified bovine lung cGMP-binding cGMP phosphodiesterase
164. Substrate- and kinase-directed regulation of phosphorylation of a cGMP-binding phosphodiesterase by cGMP
165. Regulatory mechanisms of particulate cyclic nucleotide phosphodiesterases
166. Identification of type II (cyclic GMP-stimulated cyclic nucleotide phosphodiesterase (CNPDE) mRNA in rat pheochromocytoma cells (PC 12)
167. Activation of rabbit liver high affinity cAMP (type IV) phosphodiesterase by a vanadyl/glutathion complex: characterization of the role of the sulfhydryl
168. 2+/calmodulin-dependent protein kinase II
169. Characterization and selective inhibition of cyclic nucleotide phosphodiesterase isozymes in canine tracheal smooth muscle
170. m cyclic AMP phosphodiesterase in itact canine trachealis by SK&F 94836: mechanical and biochemical responses
171. Purification of cyclic adenosine monophosphate phosphodiesterase from human platelets using new-inhibitor sepharose chromatography
172. Multicenter trial of oral enoximone in patients with moderately severe congestive heart failure
173. Identification of a high affinity binding site for cardiotonic phosphodiesterase inhibitors in sarcoplasmic reticulum (SR) vesicles
174. Concanavalin A stimulates the rolipram-sensitive isoforms of cyclic nucleotide phosphodiesterase in rat thymic lymphocytes
175. Dihydro- and tetrahydroisoquinolines as inhibitors of cyclic nucleotide phosphodiesterases from dog heart
176. Inhibitors of cyclic AMP phosphodiesterase 2
177. Inhibitors of cyclic AMP phosphodiesterase. 3. Synthesis and biological evaluation of pyridol and imidazolyl analogues of 1,2,3,5-tetrahydro-2-oxoimidazo[2,1,-b]quinazoline
178. Potential antidepressant activity of rolipram and other selective cyclic adenosine 3′, 5′-monophosphate phosphodiesterase inhibitors
179. Effects of pH on allosteric and catalytic properties of the guanosine cyclic 3′, 5′-phosphate stimulated cyclic nucleotide phosphodiesterase from calf liver
180. 1-(4-Aminobenzyl)-and 1-(4-aminopheny) isoquinoline derivatives: synthesis and evaluation as potential irreversible cyclic nucleotide phosphodiesterase inhibitors
181. 18O labeling
182. Calmodulin-stimulated cyclic nucleotide phosphodiesterases
183. Insulin stimulation of cyclic AMP phosphodiesterase is independent from the G-protein pathways involved in adenylate cyclase regulation
184. Multiple molecular forms of phosphodiesterase: an overview
185. A new generation of phosphodiesterase inhibitors: multiple molecular forms of phosphodiesterase and the potential for drug selectivity
186. Subclasses of cyclic AMP-specific phosphodiesterase in left ventricular muscle and their involvement in regulating myocardial contractility
187. Role of cyclic AMP in regulating cardiac muscle contractility: novel pharmacological approaches to modulating cyclic AMP degradation by phosphodiesterase
188. Selective alteration of the activity of the multiple forms of adenosine 3′, 5′-monophosphate phosphodiesterase of rat cerebrum
189. Methylxanthine inhibitors of phosphodiesterases
190. New cardiotonic agents—a promising apprach for treatment of heart failure
191. Purification and Partial Characterization of membrane-associated type II (cGMP-activatable) cyclic nucleotide phosphodiesterase from rabbit brain
192. Correlation of cell-free brain cyclic nucleotide phosphodiesterase activities to cyclic AMP decay in intact brain slices
193. Regulation of cAMP metabolism in PC12 cells by type II (cGMP-activatable) cyclic nucleotide phosphodiesterase
194. Type II (cGMP-stimulated) cyclic nucleotide phosphodiesterase regulates cyclic AMP metabolism in PC 12 cells
195. Differential inhibition of human neutrophil functions
196. Complex effects of inhibitors on cyclic GMP-stimulated cylcic nucleotide phosphodiesterase
197. Rolipram as a discriminative stimuli: transfer to phosphodiesterase inhibitors
198. Photoaffinity labeling of high-affinity cGMP-specific non-catalytic segments
199. Griseolic Acid, aAMP phosphodiesterase inhibitor, and its ester: increase in cellular cAMP levels and reduction of intraocular pressure